Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current Options in the Diagnosis and Treatment of Monkeypox

Current Options in the Diagnosis and Treatment of Monkeypox Purpose of ReviewThis review summarizes the current options for human monkeypox virus diagnostic testing, vaccination, and treatment.Recent FindingsInformation on non-lesion monkeypox virus diagnostic testing is limited to small studies with unclear sensitivities and specificities. Early data on the JYNNEOS vaccine has shown a lower incidence of monkeypox infection among vaccinated individuals. Drug options for human monkeypox, which include tecovirimat, cidofovir, brincidofovir, and vaccinia immune globulin intravenous, are limited without an FDA-approved medication and data on drug efficacy pending.SummaryData on non-lesion-based tests for human monkeypox infection, though limited, seems promising for certain clinical manifestations and to potentially screen asymptomatic patients if there is conclusive evidence of asymptomatic transmission. Vaccination with JYNNEOS appears effective in the prevention of monkeypox infection in early data. Of the limited medications available for monkeypox, tecovirimat’s safety profile appears to be the best with data suggestive of efficacy though further conclusive evidence from clinical trials is lacking. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Fungal Infection Reports Springer Journals

Current Options in the Diagnosis and Treatment of Monkeypox

Current Fungal Infection Reports , Volume 16 (4) – Dec 1, 2022

Loading next page...
 
/lp/springer-journals/current-options-in-the-diagnosis-and-treatment-of-monkeypox-EUrtqRFLcQ
Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
ISSN
1936-3761
eISSN
1936-377X
DOI
10.1007/s12281-022-00448-8
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewThis review summarizes the current options for human monkeypox virus diagnostic testing, vaccination, and treatment.Recent FindingsInformation on non-lesion monkeypox virus diagnostic testing is limited to small studies with unclear sensitivities and specificities. Early data on the JYNNEOS vaccine has shown a lower incidence of monkeypox infection among vaccinated individuals. Drug options for human monkeypox, which include tecovirimat, cidofovir, brincidofovir, and vaccinia immune globulin intravenous, are limited without an FDA-approved medication and data on drug efficacy pending.SummaryData on non-lesion-based tests for human monkeypox infection, though limited, seems promising for certain clinical manifestations and to potentially screen asymptomatic patients if there is conclusive evidence of asymptomatic transmission. Vaccination with JYNNEOS appears effective in the prevention of monkeypox infection in early data. Of the limited medications available for monkeypox, tecovirimat’s safety profile appears to be the best with data suggestive of efficacy though further conclusive evidence from clinical trials is lacking.

Journal

Current Fungal Infection ReportsSpringer Journals

Published: Dec 1, 2022

Keywords: Human monkeypox virus; Monkeypox outbreak; Monkeypox PCR; Tecovirimat; Brincidofovir; Cidofovir

References